Leadership
Our leadership team has decades of experience shaping strategy and innovation across the global pharmaceutical industry.

Our leadership team has decades of experience shaping strategy and innovation across the global pharmaceutical industry.


Chief Executive Officer

Chief Scientific Officer

Sr. Biology Consultant

Toxicology Consultant

Neurodegeneration Scientific Advisor

Neuroinflammation Scientific Advisor

Neurodegeneration Scientific Advisor

Clinical Consultant

Financial Consultant

Board Chair

Board Member/CEO
Chief Executive Officer
Dr. Cowen is currently the CEO of TicTwo Therapeutics. Previously, he was COO, CEO and President & CEO at ImmunoMet Therapeutics Inc. a VC funded early stage oncology biotech company for six years where he built the management team, raised $30 million in financing and progressed the lead molecule through two successful Phase 1 studies and into a Phase 2 study in pancreatic cancer at MD Anderson Cancer Center. He also led Corporate Development at Milestone Pharmaceuticals, led Business Development at PDS Biotechnology and held seven positions across four divisions during his 14 years at Merck & Co.
Dr. Cowen is on the Board of Directors for ImmunoMet Therapeutics and has served on the Board of Directors for INCON and Atrin Pharmaceuticals (now Aprea Pharmaceuticals).
Dr. Cowen trained as a research scientist and was an NIH Postdoctoral Fellow at the Univ. of Penn. He holds a BA in Physics with high honors from Brandeis Univ., a PhD in Biophysics from the Univ. of Illinois and an MBA in Strategy and Finance from the Tepper School of Business at Carnegie Mellon Univ.
Chief Scientific Officer
Dr. Ryan Moslin has over 15 years of experience in the pharmaceutical industry, spanning drug discovery, venture capital and Medical Affairs. He is currently the Chief Scientific Officer at TicTwo Therapeutics.
From 2023 to 2024, Dr. Moslin worked at the venture capital firm Curie.Bio where he guided scientific assessments and developed strategy for seed-stage biotech companies. Prior to that, he was part of the global Medical Affairs team at Bristol Myers Squibb (BMS).
The majority of Dr. Moslin’s career, from 2010 to 2022, was within BMS Medicinal Chemistry, where he was one of the pioneers of allosteric TYK2 inhibitors and was the lead inventor of deucravacitinib. Additionally, he was the program lead for the BMS clinical TYK2 CNS program.
Dr. Moslin earned his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT) in 2006 and completed his postdoctoral research in materials science at MIT in 2010.
Sr. Biology Consultant
Robert N. Willette, PhD is an independent consultant and President of PoC Pharma Consulting, LLC. Previously, he served at GlaxoSmithKline (GSK) as VP, Unit Head, and Fellow in the Heart Failure & Renal Discovery Performance Unit, guiding programs from preclinical discovery to clinical proof of concept. He earned a PhD in Pharmacology from Rutgers University and completed postdoctoral training in neurobiology and cardiopulmonary biology at the VA in New Jersey and Weill Cornell. Over 40+ years in R&D, he has authored 150+ peer-reviewed papers and led cardiopulmonary, cerebrovascular, and renal projects. He received the AHA Robert Siekert Award and the George Koelle Award, served as President of the Mid-Atlantic Pharmacology Society, and taught as an adjunct professor at Thomas Jefferson University. He is a scientific advisor, a mentor at UPenn, a director at Artiam Bio, and PI on a 2025 NIA SBIR.
Toxicology Consultant
Dr. Rex Denton, Toxicologist/Pre-Clinical Development, received his education and training from Nazareth University, University of Rochester, Bethesda USUHS/Naval Medical Center, and Yale University. During his twenty-one years at Bristol-Myers Squibb, he played significant roles in the development and commercialization of medicines aimed at alleviating human suffering caused by disease. His contributions include involvement in drug candidate molecule projects, chairing multiple initiatives, and overseeing the pre-clinical toxicology for eleven First-In-Human trials. Dr. Denton shares inventor status for medicines such as Nurtec and Zavspret. He contributed to the development of Ducravacitinib and related follow-on molecules. Additionally, he advanced three other full phase development molecules, currently in clinical trials/heading toward New Drug Application (NDA) status. Dr. Denton now focuses on Neuroscience, Immunology, Cancer/Oncology, and Metabolic Disorders to advise Pharma, biopharma, startup companies and University incubators on Investigational New Drug (IND) strategies.
Neurodegeneration Scientific Advisor
Mark W. Albers is a neurologist specializing in memory and olfactory disorders. He earned his PhD in organic chemistry from Harvard University in Stuart Schreiber’s lab and his MD from the Harvard-MIT HST program. After residency in internal medicine and neurology at Massachusetts General and Brigham and Women’s Hospitals, he conducted research with Richard Axel and practiced behavioral neurology at Columbia. He now treats patients with memory and smell disorders at MGH. His research explores olfactory biomarkers and drug repurposing for neurodegeneration, leading the NADALS Basket Trial of ALS and Alzheimer’s patients. He directs the Massachusetts Life Sciences Neuroscience Consortium and Center for Alzheimer’s Therapeutic Science and is a core faculty at Harvard’s Systems Pharmacology Lab.
Neuroinflammation Scientific Advisor
Dr. Wei Cao is a professor in the Department of Anesthesiology at the University of Texas Health Science Center in Houston (UTH). She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill and completed postdoctoral training at the Scripps Research Institute in San Diego, California. Prior to UTH, Dr. Cao worked as a faculty member at the University of Texas MD Anderson Cancer Center and Baylor College of Medicine. Her current research centers on defining the mechanisms by which neuroinflammation arises and affects the pathogenesis of Alzheimer’s Disease, brain aging, and beyond.
Neurodegeneration Scientific Advisor
Associate Professor Markus Hofer is a clinical neuropathologist and researcher at the Charles Perkins Centre and the School of Life and Environmental Sciences at the University of Sydney, Australia. His work focuses on neuroimmunology and the molecular mechanisms that drive brain inflammation, with particular relevance to rare interferon-mediated disorders such as Aicardi-Goutières syndrome and neurodevelopmental disease. His research combines classical neuropathology with advanced molecular tools to uncover targets for therapeutic intervention and improve understanding of how immune signalling affects brain development and disease. He also serves as consultant neuropathologist at the NSW Tissue Resource Centre.
Clinical Consultant
Ajay Verma, MD, PhD, is a neurologist, neuroscientist, and clinical development executive with over 20 years of industry experience spanning Merck, Novartis, Biogen, United Neuroscience, Codiak Biosciences, Yumanity Therapeutics and Twilight Bioscience. He has led multiple biomarker driven CNS development programs, integrating fluid, imaging, electrophysiologic, and digital biomarkers into adaptive and experimental medicine trial designs to de risk decision making in early development. His work has emphasized target engagement, pharmacodynamic and pathway biomarkers, and patient stratification strategies across neurodegenerative, pain, and neuroinflammatory indications. Ajay previously served as Professor of Neurology at the Uniformed Services University and Staff Neurologist at Walter Reed Army Medical Center. He is currently General Partner at Formation Venture Engineering and FVE Foundry and serves as Clinical Development Advisor to TicTwo Therapeutics, where he supports biomarker strategy, experimental medicine paradigms, and clinical development strategy for CNS penetrant TYK2 inhibitor programs.
Financial Consultant
Michael Bell is a corporate finance executive with over 25 years of experience in financial strategy and capital formation. A UK Chartered Accountant and CPA, he holds an MBA from Columbia University and an MSc in Economics from the London School of Economics.
For the past two decades, Michael has focused on the life sciences sector, advising companies on fundraising strategies, capital structuring, and exit planning. As a consulting Chief Financial Officer, he provides independent, strategic guidance on raising capital—both dilutive and non-dilutive—deal structuring, negotiations, and operational finance.
He has successfully secured over $250 million in equity funding for clients, which include ImmunoMet Therapeutics, Aerie Pharmaceuticals, Aerpio Pharmaceuticals, Catalyst Biosciences, Ferrokin Biosciences, and Topaz Pharmaceuticals.
Board Chair
Pranav Amin, the Managing Director of Alembic Pharmaceuticals Limited heads the international business unit of the organisation. After joining the organisation, he took charge as a Managing Director in 2016. A graduate in Economics/Industrial Management from the Carnegie Mellon University in Pittsburgh, USA and MBA in International Management from Thunderbird, USA. He is a great people leader and steers the organisation through involvement, empowerment and autonomy. He holds directorship in Elecon Engineering Company Limited, Max Healthcare Institute Limited and Shreno Engineering Limited, Incozen Therapeutics Private Limited and is a designated partner in Viramya Packlight LLP.
Board Member/CEO
Dr. Cowen is currently the CEO of TicTwo Therapeutics. Previously, he was COO, CEO and President & CEO at ImmunoMet Therapeutics Inc. a VC funded early stage oncology biotech company for six years where he built the management team, raised $30 million in financing and progressed the lead molecule through two successful Phase 1 studies and into a Phase 2 study in pancreatic cancer at MD Anderson Cancer Center. He also led Corporate Development at Milestone Pharmaceuticals, led Business Development at PDS Biotechnology and held seven positions across four divisions during his 14 years at Merck & Co.
Dr. Cowen is on the Board of Directors for ImmunoMet Therapeutics and has served on the Board of Directors for INCON and Atrin Pharmaceuticals (now Aprea Pharmaceuticals).
Dr. Cowen trained as a research scientist and was an NIH Postdoctoral Fellow at the Univ. of Penn. He holds a BA in Physics with high honors from Brandeis Univ., a PhD in Biophysics from the Univ. of Illinois and an MBA in Strategy and Finance from the Tepper School of Business at Carnegie Mellon Univ.